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The NLRC4 inflammasome assembles in response to detection of bacterial invasion, and
NLRC4 activation leads to the production of IL-1b and IL-18 together with pyroptosis-
mediated cell death. Missense activating mutations in NLRC4 cause autoinflammatory
disorders whose symptoms are distinctly dependent on the site of mutation and other
aspects of the genetic background. To determine the involvement of IL-1b and IL-18 in the
inflammation induced by NLRC4 mutation, we depleted IL-1b, IL-18, or both cytokines in
Nlrc4-transgenic mice in which mutant Nlrc4 is expressed under the MHC class II
promoter (Nlrc4-H443P-Tg mice). The deletion of the Il1b or Il18 gene in Nlrc4-H443P-
Tg mice reduced the neutrophil numbers in the spleen, and mice with deletion of both
genes had an equivalent number of neutrophils compared to wild-type mice. Deletion of
Il1b ameliorated but did not eliminate bone marrow hyperplasia, while mice deficient in Il18
showed no bone marrow hyperplasia. In contrast, tail bone deformity remained in the
presence of Il18 deficiency, but Il1b deficiency completely abolished bone deformity. The
decreased bone density in Nlrc4-H443P-Tg mice was counteracted by Il1b but not Il18
deficiency. Our results demonstrate the distinct effects of IL-1b and IL-18 on NLRC4-
induced inflammation among tissues, which suggests that blockers for each cytokine
should be utilized depending on the site of inflammation.
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Inflammasomes are composed of an assembler protein such as a nucleotide-binding domain-
containing proteins, a leucine-rich family protein, ASC and caspase-1, and inflammasome
stimulation leads to the maturation and secretion of the IL-1b and IL-18 cytokines (1–3).
Inflammasome activation is induced by pathogen-associated molecular patterns as well as
damage-associated molecular patterns. The activation of the inflammasome is accompanied by
pyroptosis-mediated cell death, which causes burst secretion of IL-1b and IL-18 (1, 4).
Hyperactivation of inflammasomes causes several types of diseases called autoinflammatory
disorders (5–8). NLRP3 mutations were initially reported in cryopyrin-associated periodic fever
syndrome (CAPS), which includes familial cold autoinflammatory syndrome, Muckle-Wells
syndrome and neonatal-onset multisystem inflammatory disease (7). The NLRC4 inflammasomeorg October 2020 | Volume 11 | Article 5917131
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secretion system, the rod and needle proteins, which directly
interact with NAIP proteins in a receptor–ligand fashion (9–
14). Once the NAIP protein binds its specific ligand, it
can bind to NLRC4, leading to NLRC4 oligomerization
(13, 14). Hyperactivation of NLRC4 by genetic mutation
causes autoinflammatory disorders characterized by CAPS,
enterocolitis, or macrophage activation syndrome (15–18),
which we hereafter call NLRC4-dysregulated diseases. Patients
with mutations in NLRC4 exhibit increases in IL-18 and
IL-1b compared to patients with diseases associated with
mutations in NLRP3. Indeed, blockade of IL-18 by IL-18BP
ameliorates disease severity in patients with NLRC4 mutations
(19, 20).
Here, we assessed the contributions of IL-1b and IL-18 to
NLRC4-dysregulated disorders. Mice that harbor a hyperactive
Nlrc4 gene spontaneously develop inflammation in the skin, liver
and bone with an increased number of neutrophils in the spleen
(15). As reported here, deletion of the Il1b gene partially
ameliorated bone marrow inflammation and reduced serum
IL-18. The deletion of Il18 completely abolished bone marrow
inflammation. In contrast, Il1b but not Il18 deficiency abolished
tail bone deformity and reduced bone density. These data
demonstrate the distinct roles of IL-1b and IL-18 in NLRC4-
dysregulated diseases and reveal that blockade of both IL-18 and
IL-1b is needed to completely suppress inflammation.MATERIALS AND METHODS
Mice
The Nlrc4-H443P-Tg mice, Il1b-deficient mice, and Il18-
deficient mice have been previously reported (15, 21, 22). All
mice were maintained under specific pathogen-free conditions in
the animal facilities at Tokushima University, Japan. All
experiments were performed in accordance with institutional
guidelines and the animal care research committee at
Tokushima University.
ELISA
Cytokines in the serum were analyzed using a Mouse G-CSF
Quantikine ELISA kit (catalog #MCS00) and mouse IL-18/IL-
1F4 ELISA kit (catalog #7625) according to the manufacturer’s
instructions (R&D Systems, MN, USA).
Flow Cytometry
Spleen single-cell suspensions were obtained and treated with
RBC lysis buffer. Cells were then incubated with rat anti-mouse
CD16/CD32 Ab followed by mAbs specific for extracellular
markers. Fluorochrome-conjugated monoclonal antibodies
specific for mouse TCRb (H57-597), CD19 (1D3), CD11b
(M1/70), and Gr-1 (RB6-8C5) were purchased from BioLegend
(San Diego, CA, USA). Neutrophils were identified as
CD11b+Gr-1high cells. Data were collected on a FACS Canto II
(BD Biosciences) flow cytometer and analyzed using FACS Diva
(BD Biosciences) or FlowJo (Tree Star, OR, USA) software.Frontiers in Immunology | www.frontiersin.org 2Histology
Ear skin samples were collected and fixed in 10% formalin
solution. Bone tissues were fixed in 10% formalin and then
demineralized in 10% EDTA. The samples were sectioned and
stained with H&E and evaluated with respect to cell influx and
edema (0, no influx or edema; 1, mild influx and edema; 2,
moderate influx and edema; and 3, severe influx and edema) and
bone marrow hyperplasia and bone deformity (0, no hyperplasia
or deformity; 1, mild hyperplasia and deformity; 2, moderate
hyperplasia and deformity; and 3, severe hyperplasia and
deformity) by semiquantitative examination.
Computed Tomography
The left foot and tai l were analyzed in vivo with
microcomputerized tomography at high resolution. The bone
density of lower limbs was calculated using Latheta software
(Latheta LCT-200, Hitachi Aloka Medical, Tokyo, Japan) 3D
morphology reconstruction was performed using 3D Slicer
(version 4.10.2). The 3D sections of paw and tail evaluated with
respect to bone deformity (0, no deformity, 1, mild; 2, moderate;
and 3, severe deformity) by semiquantitative examination.
Statistical Analysis
For all experiments, the significant differences between groups
were calculated using Student’s t-test for unpaired data or one-way
ANOVA. Differences were considered significant when p < 0.05.RESULTS
Both IL-1b and IL-18 Are Required for
Inflammation in Nlrc4-H443P-Tg Mice
To assess the involvement of IL-1b and IL-18 in Nlrc4-H443P-
Tg mice, we crossed Nlrc4-H443P-Tg mice with Il1b- or Il18-
deficient (Nlrc4-H443P-Tg/Il1b−/− or Nlrc4-H443P-Tg/Il18−/−,
respectively) mice or with mice deficient in both genes
(Nlrc4-H443P-Tg/Il1b−/−Il18−/−). We have previously reported
that Nlrc4-H443P-Tg mice have an increased number of
CD11b+Gr-1high neutrophils in the spleen (15). We first
evaluated the number of CD11b+Gr-1high neutrophils in the
spleens of Nlrc4-H443P-Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−,
and Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice at 8 weeks (Figure
1A). The number of CD11b+Gr-1high neutrophils at 8 weeks
was comparable among control, Nlrc4-H443P-Tg/Il1b−/−, Nlrc4-
H443P-Tg/Il18−/−, and Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice
(Figure 1A). An increase in CD11b+Gr-1high neutrophils was
detected in Nlrc4-H443P-Tg mice at 20 weeks (Figure 1B). The
number of CD11b+Gr-1high neutrophils was reduced in both
Nlrc4-H443P-Tg/Il1b−/− and Nlrc4-H443P-Tg/Il18−/− mice, and
the number in Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice was almost
equivalent to that in wild-type mice (Figure 1B). The number of
T cells and B cells are also increased in Nlrc4-H443P-Tg mice,
which was reduced in the absence of IL-1b and IL-18 (Figure
1B). In further experiments, to analyze the effect of IL-1b and IL-
18, we used mice at the age of 20 weeks.
We next tested the serum levels of cytokines in mice at the age
of 20 weeks. IL-18 was increased in the Nlrc4-H443P-Tg mice,October 2020 | Volume 11 | Article 591713
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the increase in IL-18 is partially dependent on IL-1b. The serum
G-CSF level was also increased in the Nlrc4-H443P-Tg mice, and
deficiency in either Il1b or Il18 reduced the level, whereas
deletion of both led to a level equivalent to that in control
mice (Figure 1D).
Blockade of IL-1b or IL-18 Ameliorates
Inflammation in Nlrc4-H443P-Tg Mice
We next analyzed the histology of ear skin, joint and bone
marrow samples from control, Nlrc4-H443P-Tg, Nlrc4-H443P-
Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−, and Nlrc4-H443P-Tg/
Il1b−/−Il18−/− mice (Figures 2A, B). The Nlrc4-H443P-Tg mice
showed massive infiltration of immune cells in the ear skin, joint
and bone marrow samples. The skin in Nlrc4-H443P-Tg mice
was thickened because of edema compared with that in wild-type
mice. Deletion of either Il1b or Il18 ameliorated cell infiltrationFrontiers in Immunology | www.frontiersin.org 3in the skin and joints (Figures 2A, B). In contrast, deletion of
Il18 almost completely abolished hyperplasia in the bone
marrow, while mice deficient in Il1b still exhibited moderate
hyperplasia in the bone marrow. Deletion of both Il1b and Il18
completely abolished inflammation in any tissues (Figures 2A, B).
These data indicate that both IL-1b and IL-18 are responsible for
inflammation in Nlrc4-H443P-Tg mice and that IL-18 has a
greater impact on bone marrow inflammation than IL-1b.
Blockade of IL-1b Is More Effective Than
That of IL-18 in Treating Bone Erosion in
Nlrc4-H443P-Tg Mice
We assessed the shapes of bones in the left foot and tail using
mCT analysis to evaluate the effect of IL-1b or IL18 on the bone
phenotype of Nlrc4-H443P-Tg mice (Figure 3). Bone deformity
was also observed in vertebrae (data not shown). Nlrc4-H443P-
Tg mice developed severe deformities of the left foot and tail withA
B
DC
FIGURE 1 | IL-1b– and Il-18–mediated inflammation in Nlrc4-H443P-Tg mice. (A) Total neutrophil numbers in the spleens of control, Nlrc4-H443P-Tg, Nlrc4-
H443P-Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−, and Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice at the age of 8 and weeks were determined (N = 8 in each group). The
neutrophils were defined as CD11b+Gr-1high cells. The data are shown as the mean ± SD. *P < 0.05; **P < 0.01. (B) Total neutrophil, T cells or B cells numbers in
the spleens of control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−, and Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice at the age of 20 weeks were
determined (N = 8 in each group). The data are shown as the mean ± SD. *P < 0.05; **P < 0.01. Serum (C) IL-18 was measured in control, Nlrc4-H443P-Tg, Nlrc4-
H443P-Tg/Il1b−/− and Nlrc4-H443P-Tg/Il18−/− mice at the age of 20 weeks (N = 5 in each group), and serum (D) G-CSF was measured in control, Nlrc4-H443P-Tg,
Nlrc4-H443P-Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−, and Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice at the age of 20 weeks (N = 5 in each group). Data are shown as the
mean ± SD. **P < 0.01.October 2020 | Volume 11 | Article 591713
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completely diminished the deformity in the foot bones and
joints. In contrast, mice deficient in Il18 showed mild
deformity in the tail bones, while Il1b-deficient mice exhibited
no tail bone deformity (Figure 3).
Bone density was also decreased in Nlrc4-H443P-Tg mice
(Figure 4). Il1b deficiency completely rescued the reduced bone
density in Nlrc4-H443P-Tg mice, while Il18 deficiency partially
reversed this reduction (Figure 4). These data suggest that IL-1b
has more important roles in bone phenotypes than IL-18 in
NLRC4-dysregulated diseases.DISCUSSION
Heterozygous mutations in NLRC4 cause several types of
autoinflammatory disorders. For instance, NLRC4 mutations
cause CAPS-like syndrome, including cold-induced
autoinflammatory syndrome and NOMID (15, 18). The clinical
phenotypes of CAPS-like syndrome caused by NLRC4 mutations
are indistinguishable from those caused by NLRP3 mutations.
NLRC4 mutations also cause infantile enteritis and macrophage
activation syndrome (16, 17). One of the characteristics of
NLRC4-dysregulated diseases is high serum IL-18, and IL-18
blockade is effective in treating macrophage activation
syndrome caused by NLRC4 mutation (19, 20). However, the
roles of IL-18 and IL-1b in NLRC4-dysregulated diseases are notFrontiers in Immunology | www.frontiersin.org 4fully understood, and thus, we tested the roles of each cytokine by
using mice in which a mutant Nlrc4 is expressed under the MHC
class II promoter in combination with Il1b and Il18 deficiency.
Our data demonstrated the distinct roles of IL-1b and IL-18 in
inflammation in the joints and skin, suggesting that the efficacy of
blockers of each cytokine depends on the regions of inflammation.
Blockade of IL-1b and Il-18 is effective for ameliorating
inflammation in Nlrc4-H443P-Tg mice, although the
contribution of each cytokine to inflammation is distinct among
tissues. Induced deficiency of Il18 is more effective than that of Il1b
in suppressing bonemarrow hyperplasia, and Il1b deficiency better
inhibited bone deformity and decreases in bone density than Il18
deficiency. One possibility to explain the distinct effects of these
cytokines in tissues would be differences in the cell types that
respond to IL-1b or IL-18. In any case, our data suggest that the
blockade of both IL-1b and IL-18 is required to completely suppress
inflammation in NLRC4-dysregulated diseases. In addition, Nlrc4-
H443P-Tgmice with deletion of both Il1b and Il18 do not show any
inflammation or any increase in neutrophils, suggesting a small
contribution of pyroptosis-mediated cell death and cell death-
associated damage-associated molecular patterns to inflammation
in NLRC4-dysregulated diseases.
NOMID patients exhibit bone deformity accompanied by joint
inflammation (23, 24). Nlrc4-H443P-Tg mice also show severe
bone deformity at the age of 20 weeks. Bone deformity is caused by
IL-1b and IL-18, but blockade of IL-18 is not enough to suppress
the deformity. On the other hand, recent studies have indicatedA
B
FIGURE 2 | IL-1b– and Il-18–mediated inflammation in the skin and joints of Nlrc4-H443P-Tg mice. (A) Histological sections of ear skin and ankle joints in control,
Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−, and Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice at the age of 20 weeks were stained with hematoxylin
and eosin. (B) The histological scores were evaluated in the ear skin and ankle joints in in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−,
and Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice at the age of 20 weeks (N = 8 in each group). Data are shown as the mean ± SD. *P < 0.05, **P < 0.01.October 2020 | Volume 11 | Article 591713
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activation syndrome caused by NLRC4mutation that is refractory
to blockade of IL-1b. Our data suggest that bone phenotypes in
NLRC4-associated NOMID might be treated with a combination
of blockers of IL-1b and IL-18. Regarding the contribution of IL-
1b and IL-18 to bone deformity, a previous study demonstrated
that IL-18 upregulates membrane-bound receptor activator of
nuclear factor kappa B ligand (RANKL) expression and soluble
RANKL production, thus increasing the ratio of RANKL/
osteoprotegerin, suggesting an effect of IL-18 on the induction
of osteoclast formation and bone resorption (25). IL-1b is involved
in osteoclast differentiation in part through the induction of
TRAF-6 downstream of the IL-1b pathway (26). Further studies
are required to clarify not only the molecular mechanism of IL-1b-
mediated bone deformity but also the roles of IL-18 in this context.
Several gene-modified mice were reported to investigate the
molecular mechanisms of autoinflammatory disorders including
CAPS. Pyrin-knock-in mice harboring mutant human B30.2
domains exhibited spontaneous bone marrow-dependent
inflammation similar to that seen in human familial
Mediterranean fever (27). This inflammation was completely
abrogated in the absence of the IL-1 receptor or the adaptor
molecule ASC. Nlrp3-knock-in mice demonstrated early mortality
mediated by myeloid cells, which was only partially dependent onFIGURE 3 | IL-1b– and Il-18–mediated bone deformity in Nlrc4-H443P-Tg mice. The tail and left foot in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b−/−, Nlrc4-
H443P-Tg/Il18−/−, and Nlrc4-H443P-Tg/Il1b−/−Il18−/− mice at the age of 20 weeks were evaluated with mCT. Red arrows, bone deformity regions (N = 5 in each
group). The scores were evaluated as shown in the Materials and Methods in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−, and Nlrc4-
H443P-Tg/Il1b−/−Il18−/− mice at the age of 20 weeks (N = 8 in each group). Data are shown as the mean ± SD. **P < 0.01.FIGURE 4 | Rescue of decreased bone density by deficiency of Il1b or Il18 in
Nlrc4-H443P-Tg mice. Bone density in control, Nlrc4-H443P-Tg, Nlrc4-
H443P-Tg/Il1b−/−, Nlrc4-H443P-Tg/Il18−/−, and Nlrc4-H443P-Tg/Il1b−/−Il18−/−
mice at the age of 20 weeks was evaluated with mCT (N = 10 in each group).
The data are shown as the mean ± SD. *P < 0.05, **P < 0.01.October 2020 | Volume 11 | Article 591713
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partial phenotypic rescue in skin and visceral disease and reduced
serum cytokines (29). Another strain of Nlrp3-knock-in mice
exhibited skin inflammation with neutrophil infiltration and a
Th17 cytokine-dominant response, which was suppressed in the
absence of the IL-1 receptor (30). The comparison of our Nlrc4-
H443P-Tg mice with the pyrin- or Nlrp3-knock-in mice side by
side would be interesting to understand the effect of each cytokine
on organ pathology induced by NLRC4 mutations.
In summary, our data demonstrate the crucial contributions
of IL-1b and IL-18 to NLRC4-dysregulated diseases but reveal
that the two cytokines have distinct roles depending on the
tissue. These data suggest that blockers of IL-1b and IL-18 should
be utilized depending on the site of tissue inflammation in
NLRC4-dysregulated diseases.DATA AVAILABILITY STATEMENT
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